Education
About Us
Working with TipRanks
Follow Us
Immunitybio Inc (IBRX)
NASDAQ:IBRX
IBRX Stock Chart & Stats
$6.15
-$0.11(-4.03%)
At close: 4:00 PM EST
$6.15
-$0.11(-4.03%)
Day’s Range― - ―
52-Week Range$1.83 - $8.28
Previous CloseN/A
Volume1.20M
Average Volume (3M)36.56M
Market Cap
$5.86B
Enterprise Value$5.82B
Total Cash (Recent Filing)$153.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Mar 03, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding984,965,150
10 Day Avg. Volume84,340,596
30 Day Avg. Volume36,558,391
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-3.65
Price to Sales (P/S)121.07
P/FCF Ratio-4.48
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue70.51
Enterprise Value/Gross Profit74.41
Enterprise Value/Ebitda-25.02
Forecast
1Y Price Target
$8.75Price Target Upside42.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial And International ExpansionRapid revenue growth, increasing unit volumes, and recent regulatory authorizations in multiple international markets indicate accelerating physician adoption and a broader commercial runway for ANKTIVA.
Durable Clinical BenefitLong‑term clinical data showing high bladder cancer–specific survival and strong cystectomy avoidance with ANKTIVA plus BCG support durable clinical benefit that can strengthen prescriber confidence.
Regulatory Pathway ClarityFDA allowing a supplemental biologics license application resubmission for ANKTIVA without requiring new clinical trials reduces regulatory risk and supports a clearer path to label expansion.
Bears Say
Conditional Approval ObligationsConditional authorizations that require significant post‑marketing commitments create risk around the timing and scope of long‑term data obligations and could delay full market access.
Durability And Endpoint UncertaintyUncertainty over whether immune restoration is durable without continued dosing, whether restored lymphocytes are fully functional, and whether regulators will accept lymphocyte counts as a trial endpoint creates development and approval risk.
Regulatory Acceptance Of Immune RestorationQuestions about whether major regulatory agencies will broadly accept the immune restoration paradigm and whether clinical benefit will be consistent across different tumor types could constrain approvals and label expansion.
ImmunityBio News
IBRX FAQ
What was Immunitybio Inc’s price range in the past 12 months?
Immunitybio Inc lowest stock price was $1.83 and its highest was $8.28 in the past 12 months.
What is Immunitybio Inc’s market cap?
Immunitybio Inc’s market cap is $5.86B.
When is Immunitybio Inc’s upcoming earnings report date?
Immunitybio Inc’s upcoming earnings report date is Mar 03, 2026 which is in 32 days.
How were Immunitybio Inc’s earnings last quarter?
Immunitybio Inc released its earnings results on Nov 04, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.037.
Is Immunitybio Inc overvalued?
According to Wall Street analysts Immunitybio Inc’s price is currently Undervalued.
Does Immunitybio Inc pay dividends?
Immunitybio Inc does not currently pay dividends.
What is Immunitybio Inc’s EPS estimate?
Immunitybio Inc’s EPS estimate is -0.09.
How many shares outstanding does Immunitybio Inc have?
Immunitybio Inc has 984,965,150 shares outstanding.
What happened to Immunitybio Inc’s price movement after its last earnings report?
Immunitybio Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went down -7.965%.
Which hedge fund is a major shareholder of Immunitybio Inc?
Currently, no hedge funds are holding shares in IBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (42.28% Upside)
$8.75 (42.28% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.0%
Last 30 Days ▲ 68.4%
Last 30 Days ▲ 68.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.36%
Trailing 12-Months
Company Description
Immunitybio Inc
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
IBRX Stock 12 Month Forecast
Average Price Target
$8.75
▲(42.28% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
66.42% Insiders
3.36% Mutual Funds
0.03% Other Institutional Investors
24.53% Public Companies and Individual Investors